title: Lipoprotein pattern and plasma lipoprotein lipase activities in patients with primary biliary cirrhosis. Relationship with increase of HDL2 fraction in Lp-X-positive and Lp-X-negative subjects.
abstract: Plasma lipids, apoprotein A-I and B in serum and in lipoprotein fractions (VLDL + LDL, HDL2, and HDL3) obtained by preparative ultracentrifugation, as well as postheparin lipoprotein lipase activity (H-TGL and LPL) were evaluated in 17 subjects with primary biliary cirrhosis (stage II and III) subdivided into two groups according to the presence or absence of lipoprotein X (Lp-X). A reduction in total lipoprotein lipase activity was observed in both patient groups, compared to controls (P less than 0.01); the hepatic lipoprotein lipase was significantly reduced (P less than 0.01) only in the Lp-X-positive group. The lipid (477.8 +/- 154.3 vs 239.6 +/- 51.1; P less than 0.01) and protein (147.4 +/- 37.1 vs 83.3 +/- 19.7; P less than 0.01) masses in the VLDL + LDL fraction of the Lp-X-positive group were increased compared to controls. In the same group, the HDL2 fraction also showed an increase in lipid (186.6 +/- 80.0 vs 77.9 +/- 21.6; P less than 0.01) and protein (133.9 +/- 60.0 vs 67.9 +/- 16.5; P less than 0.01) masses; in addition, the HDL2 percent lipid composition was different in the two patient groups, showing a decrease in esterified cholesterol (20.4 +/- 3.6 vs 25.7 +/- 2.2; P less than 0.01) and an increase in phospholipids (59.2 +/- 2.9 vs 54.8 +/- 2.6; p less than 0.01) in the Lp-X-positive group.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Internal Medicine, University of Padua, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Baldo-Enzi
authors.forename: M R
authors.initials: MR
authors.lastname: Baiocchi
authors.forename: M
authors.initials: M
authors.lastname: Grotto
authors.forename: A R
authors.initials: AR
authors.lastname: Floreani
authors.forename: M
authors.initials: M
authors.lastname: Zagolin
authors.forename: M
authors.initials: M
authors.lastname: Chiaramonte
authors.forename: F
authors.initials: F
authors.lastname: Cera
authors.forename: R
authors.initials: R
authors.lastname: Fellin
mesh_terms: D001055:Apolipoproteins B / Q000032:analysis; D002788:Cholesterol Esters / Q000032:analysis; D005260:Female; D006801:Humans; D008071:Lipoprotein Lipase / Q000037:antagonists & inhibitors / Q000378:metabolism*; D008073:Lipoprotein-X / Q000378:metabolism*; D008074:Lipoproteins / Q000378:metabolism*; D008075:Lipoproteins, HDL / Q000378:metabolism*; D008077:Lipoproteins, LDL / Q000378:metabolism; D008079:Lipoproteins, VLDL / Q000378:metabolism; D008105:Liver Cirrhosis, Biliary / Q000097:blood / Q000201:enzymology / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010743:Phospholipids / Q000032:analysis; D011506:Proteins / Q000032:analysis
chemical_list: D001055:Apolipoproteins B; D002788:Cholesterol Esters; D008073:Lipoprotein-X; D008074:Lipoproteins; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D010743:Phospholipids; D011506:Proteins; D008071:Lipoprotein Lipase